FDA approves biosimilar drug for anemia treatment
The Food and Drug Administration on Tuesday approved Retacrit as a biosimilar to treat anemia caused by chronic kidney disease and chemotherapy.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Anemia | Chemotherapy | Chronic Kidney Disease | Food and Drug Administration (FDA) | Health | Urology & Nephrology